Home Innovation That Matters

Innovation That Matters

Inside Perspectives: Gene Editing Takes Center Stage

Depending on the scientific expert, gene editing is just another sophisticated gene therapy tool in the fight against human diseases or a technological advance so remarkable it has the potential to change the course of human development and that of every other genus and...

Inside Perspectives on Gene Editing: An Interview with Genomics Pioneer George M. Church of Harvard University

Harvard University’s George M. Church is among the world’s leading scientific pioneers in genomics and biotechnology. The genetics professor at Harvard Medical School and Massachusetts Institute of Technology has founded numerous biotech companies that apply his breakthrough technological innovations to medical diagnostics, therapeutics, and synthetic biology.  Church...

Inside Perspectives on Gene Editing: An Interview with Agenovir CEO Dirk Thye

Using its deep virology expertise and targeted genome editing technologies, Agenovir is on a mission to develop novel antiviral therapeutics, bringing hope to millions of patients who suffer from devastating, persistent viral infections. In particular, the South San Francisco start-up is using CRISPR-Cas9 technology to create topical...

Inside Perspectives on Gene Editing: An Interview with MPM Capital’s Mitchell Finer

MPM Capital Managing Director Mitchell H. Finer, Ph.D. – a 30-year gene and cell therapy veteran – describes the relatively new science of gene editing, or genome engineering, as “very exciting.” But he also is quick to add that genome engineering as a marketed...

Inside Perspectives on Gene Editing: An Interview with Cellectis CEO André Choulika

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). Based in New York City and Paris, the company is capitalizing on its 17 years of expertise in gene editing. Built on its flagship...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi NextCODE Completes $240 Million Series B Financing

We are pleased to announce that WuXi NextCODE has successfully completed a $240 million Series B financing. The company extended and completed the Series...